Sharon B. was shocked when she was diagnosed with stage 4 melanoma at age 22. She joined a clinical trial of the immunotherapy ipilimumab (Yervoy®), and has been in remission ever since.
To celebrate her survivorship, and spread the word about life-saving immunotherapies, Sharon proudly participates in CRI's Answer to Cancer cycling event and 5K family fun run/walk, and is raising funds to support the Cancer Research Institute.
Watch her story here.
In 2004, I was finishing up my Master’s in Elementary Education, and my fiancé Rob, now my husband, and I were planning out our lives together. He had accepted a job in Washington, D.C., and I was going to teach there in the fall. We rented an apartment and moved in. Then, after going to the doctor for what I thought was a bad case of bronchitis, we got the news that changed everything: I had stage 4 melanoma. I was 22. It seemed like my life was over.
They started me on high dose chemotherapy just a few days before the wedding. Chemo was horrific. I was sick day in and day out. I spent that entire first year of marriage in a haze. The chemo made me unable to function and gave me crippling neuropathy. But even worse, the chemo didn’t work. So after that, I was given interleukin-2, which didn’t work for me either. The tumors continued to grow and the drug made my skin peel off. Both treatments left me feeling broken.
When my oncologist, Dr. Jedd Wolchok, told me about a new type of therapy that was currently in the trial phases, it sounded like it could be the light at the end of the tunnel that we had been searching for. I just said “Sign me up!” I didn’t need time to think about it. Nothing up until this point had worked.
I started receiving ipilimumab (Yervoy®), an immunotherapy that “takes the brakes off” the immune system. After four rounds of treatment, Dr. Wolchok told me that the drug was working. I was dumbstruck. I had become so used to the treatments failing, that I expected more of the same. But this time, my tumors had shrunk by 60%. He said that the radiologist called up to make sure that he had the correct patient because he had never seen a response like this.
I have been in remission for eight years now.
After all my treatments were said and done, I couldn’t shake the feeling that the cancer was going to come back, so I continued with my poor eating habits. I knew that in order to lose the weight it was going to take time and effort. I didn’t think I had either. That was until I had my kids. They deserved a healthy mom. A mom that could run and play. But most importantly, one that would live long enough to see them grow up. So I changed. It’s as simple as that. I completely changed what I ate, and I started to exercise. Over the course of a year and a half, I lost over 160 lbs. I’m now a personal trainer/fitness instructor and strive to help others in their health and fitness journeys.
Provide guidance and encouragement to others going through their journey with cancer immunotherapy treatment.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
A recent diabetes-related discovery by CRI Lloyd J. Old STAR Dr. Andrea Schietinger has promising implications for cancer immunotherapy
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.